Akuru Pharma

Akuru is focusing on exploiting the abnormal expression of transporter proteins in kidney cancer for developing novel diagnostic and treatment modalities.

The founders of Akuru Pharma are using a bioinformatics platform for identification of novel surface molecules that can serve as biomarkers for kidney cancer, with particular focus on transporter proteins. Using this platform the founders, as part of their research at Lund University, identified a novel and highly specific biomarker for ccRCC that can be utilized for both diagnostic and therapeutic purposes. The inherent properties of this biomarker offers unique treatment opportunities, based on uptake of cytotoxic substrates and/or radionuclide therapy.

Kategorier: Biotech, Diagnostics, Pharma

Gå till Akuru Pharmas hemsida